New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100 million investment.
The UK’s capability to manufacture vaccines has received a substantial boost yesterday, as the government announced an additional £100 million to ensure that any successful COVID-19 vaccine can be produced at scale in the UK.
The investment will fund a state-of-the-art Cell and Gene Therapy Catapult Manufacturing Innovation Centre to accelerate the mass production of a successful COVID-19 vaccine in the UK. Due to open in December 2021, the Centre will have the capacity to produce millions of doses each month, ensuring the UK has the capabilities to manufacture vaccines and advanced medicines, including for emerging diseases, far into the future.
Located in Braintree, Essex, the government initiative will upgrade an existing facility to create a fully-licensed manufacturing centre. Doing so will increase the UK’s ability to respond to diseases like coronavirus and to prepare for potential future pandemics while creating new, high-skilled jobs to fuel the UK’s economic recovery.
The new centre will complement the Vaccines Manufacturing and Innovation Centre (VMIC), which is currently under construction in Oxfordshire thanks to a £93 million investment from the government. Once complete next year, the facility will have the capacity to produce enough vaccine doses to serve the entire UK population at scale.
While the centre is under construction, the government has invested an additional £38 million to establish a rapid deployment facility, opening later this summer, that will support efforts to ensure a successful vaccine is widely available to the public as soon as possible.
Business Secretary Alok Sharma said:
To support these enhanced vaccine manufacturing capabilities, the government will invest an additional £4.7 million for the Cell and Gene Therapy Catapult to ensure that the UK has the best skills and expertise through the development of virtual and physical national Centres for Advanced Therapies Training and Skills, in partnership with industry.
The facilities and online training platform will provide industry-standard skills and experience in advanced gene therapy and vaccine manufacturing, including sterile techniques for Good Manufacturing Practice which is the minimum standard that a medicines manufacturer must meet in their production processes.
Employment in the cell and gene therapy sector is predicted to reach over 6,000 jobs by 2024, with over 3,000 in manufacturing and bioprocessing.
Matthew Durdy, CEO, Cell and Gene Therapy Catapult commented:
Kate Bingham, Chair of the Vaccines Taskforce said:
As well as addressing the immediate need to produce a COVID-19 vaccine, the new Cell and Gene Therapy Centre, developed with Innovate UK and the Cell and Gene Therapy Catapult, will be at the forefront of the growing UK cell and gene therapy industry. Scientists and researchers based in the centre will accelerate the time taken for new treatments to be delivered to patients by developing cutting-edge therapies to treat life changing diseases, such as diabetes, heart disease and cancer.
The UK is at the forefront of international efforts to research and develop a COVID-19 vaccine and has provided £131 million funding to University of Oxford and Imperial College London to accelerate their work on 2 vaccine candidates.
This follows news on 20 July that the government secured early access to 90 million vaccine doses from the BioNTech/Pfizer alliance and Valneva as part of its strategy to build a portfolio of promising new vaccines to protect the UK from COVID-19. In addition, treatments containing COVID-19-neutralising antibodies have been secured from AstraZeneca to protect those who cannot receive vaccines.